Apogee Therapeutics, Inc.
APGE
Classificação em ações
#2358
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Preço da ação
$135.07
Última sincronização: 2026-09-04
Valor de mercado
$8.36B
Variação (1 dia)
0.00%
Variação (1 ano)
144.91%
País
US
Negociar Apogee Therapeutics, Inc. (APGE)
Categoria
Healthcare
EPS de Apogee Therapeutics, Inc. (APGE)
EPS em June 2026 TTM: $-4.34
De acordo com os últimos relatórios financeiros e o preço das ações da Apogee Therapeutics, Inc., o EPS atual da empresa (TTM) é $-4.34. No final de 2023, a empresa teve um EPS de $-1.66, um aumento em relação a ao EPS de 2022, que foi de $-0.79.
Histórico de EPS da Apogee Therapeutics, Inc. de 2022 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $-4.34 | 31.52% |
| 2024 | $-3.30 | 98.80% |
| 2023 | $-1.66 | 110.13% |
| 2022 | $-0.79 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | -499.08% |
US
|
|
| $-7.98 | 83.87% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -739.17% |
NL
|
